Subscribe to Updates in Healthcare

RSS By Email

RSS By RSS

Add to Google Reader or Homepage

Subscribe in Bloglines


The Expertise Imperative and Compliance Technology
Access to a diverse array of specialized expert inputs drives superior decisions in every organizational context: within corporations, by investors and consultancies, and within nonprofits. When decision makers are confident of their decision inputs, they can respond more quickly and creatively to challenges and opportunities.




This page may include content provided by Council Members, your access to which is subject to the Terms of Use.
Find Out More

Study Group: Oncologists Specializing in Hematologic Malignancies in the U.S.(?)

Council Members in this Study Group: 437

This study group may include physicians, care providers, and researchers specializing in internal medicine, cardiology, oncology, dermatology, emergency medicine, family medicine, neurology, obstetrics-gynecology, psychiatry, radiology, nursing, optometry, genetics, and mental health. It may also include experts knowledgeable on diagnostic labs, disease management, medical devices, long term care, surgery centers, health management, pharma, and biotechnology, among others.

Request a survey with this Study Group







Leading Experts in this Study Group

What is a GLG Leader?
Donald Fleming, MD, Division Head of Hematology and Oncology, Davis Health System, Inc.Donald Fleming, MD
Division Head of Hematology and Oncology
Davis Health System, Inc.

Donald Fleming, MD, is the Head of Hematology-Oncology at the Medical Center of Vincennes. Previously, Dr. Fleming was a Tenured Professor in the Division of Hematology-Oncology at University of Louisville. He has published over 25 manuscripts in peer-reviewed journals and remains involved in clinical...

Taral Patel, MD, Oncologist, Mid Ohio Oncology Hematology Inc.Taral Patel, MD
Oncologist
Mid Ohio Oncology Hematology Inc.

Taral Patel, MD, is an Oncologist in private practice with Mid Ohio Oncology-Hematology, Inc. He treats patients with both cancer and blood disorders. Dr. Patel has been a principal investigator for multiple clinical trials in colon cancer, lung cancer, lymphoma, and growth factor. He has been on the...

Eric Jacobsen, MD
Instructor in Medicine
Dana-Farber Cancer Institute, Harvard Medical School

Eric Jacobsen, MD, is a Medical Oncologist and Hematologist in the Hematology/Oncology Department at Dana Farber Cancer Institute in Boston, Massachusetts. His clinical focus is on lymphoma and is very involved in Phase II/III clinical trials for new compounds as well as stem cell transplantation.

Brian Abbott, MD, Medical Director of Hematology, Big Sky OncologyBrian Abbott, MD
Medical Director of Hematology
Big Sky Oncology

Brian Abbott, MD, is the Medical Director of Hematology at Big Sky Oncology and Sletten Cancer Institute in Great Falls, Montana. His specialties include acute and chronic leukemias (AML, ALL, CML, CLL), all forms of lymphomas including Non-Hodgkin’s and Hodgkin's Lymphoma, myelomas, bone and marrow...

Michael Grossbard, MD
Professor of Clinical Medicine
Columbia University College of Physicians and Surgeons

Michael Grossbard, MD, is a Professor of Clinical Medicine at Columbia University College of Physicians and Surgeons and the Chief of Hematology-Oncology at St. Luke's-Roosevelt Hospital and Beth Israel Medical Center in New York City. His clinical research is in monoclonal antibodies, non-Hodgkin's...

Donald Tsai, MD PhD
Assistant Professor of Medicine
University of Pennsylvania Cancer Center

Donald Tsai, MD, PhD, is an Assistant Professor of Medicine at the University of Pennsylvania Cancer Center. Dr. Tsai specializes in the treatment of hematological malignancies such as leukemia, multiple myeloma, lymphoma, Hodgkin's disease, myelodysplastic syndromes (MDS), and bone marrow transplantation....

Alan List, MD
Director, Translational and Clinical Research
Moffitt Cancer Center

Alan List, MD, is a Medical Oncologist and serves as Executive Vice President and Physician-in-Chief at the Moffitt Cancer Center in Tampa, Florida. Dr. List is an expert in myelodysplastic syndromes (MDS) and acute myeloid leukemia (AML). Previously, he spent 15 years at the Arizona Cancer Center....

GLG NewsSMAnalyses by this Study Group's Experts(?)

Opinions and analyses expressed in GLG News are solely those of the author. See the Terms of Use for details.
GSK's Lapatanib: ways from competing with Herceptin | 06-30-2008
Author: GLG Expert Contributor

In a recent JCO article, Laptanib showed clinical efficacy and acceptable safety in a non-randomized trial involving newly diagnosed patients with advanced oe metastatic breast cancer. Larger trials are needed to confirm efficacy and explore if it is more potent than Genentech's Herceptin. For now,...

Avastin for front-line treatment of metastatic breast cancer: Not a big market | 06-30-2008
Author: GLG Expert Contributor

Avastin's recent FDA approval for m-breast cancer ( m-BCA) was lukewarm at best with no overall survival benefit yet and modest PFS data. European regulatory agencies usually require cost efficacy data and more strict data, which are not readily available for Roche/Genetech. The British market is not...

Transgene's vaccine for SCLC: Promising, BUT need to await survival and Phase III data | 06-09-2008
Author: GLG Expert Contributor

Tarnsgene's cancer vaccine TG 4010 increased response rates and progression free survival when added to chemotherapy in patients with advanced small cell lung cancer. The overall survival rates and time to progression were not much different in the 2 treatment groups. The vaccine is novel and efficacy...

Trovax for renal cell carcinoma: not much potential | 06-05-2008
Author: GLG Expert Contributor

The efficacy of the immunotherapeutic" vaccine" Trovax in 3 separate small phase II trials in combination with interferon alpha or IL-2 was modest at best. With availability of 3 targeted agents for this disease ( Nexavar, Sutent, and Torisel) , the chances of such as an agent are very limited.

Chinese generics: Low prices bu qulaity reputation will favor India | 06-02-2008
Analysis of: China Muscles In On The Generics Industry | www.pharmalot.com
Author: GLG Expert Contributor

China, buoyed by its recent economic boom, is invading industrilaized nation markets with many generic compounds , from pain killers to AIDS drugs. Chinese drugs are cheap, but have reputation for poor quality , especially with recent heparin fiasco. India has had a good track record with generics and...

View All GLG News by members of this Study Group

Most Common Company Types:

  • Academic Medical Center/Hospital or Clinic
  • Office Based Private Practice or Clinic
  • Non-Academic Community Hospital or Clinic
  • Academic Institution*

Most Common Job Types:

  • Physician - Attending Physician
  • Physician - Director
  • Physician - Division Head
  • Director
  • Owner

GLG's 750+ Clients Include:

40 of the leading 50
global mutual funds
15 of the leading 20
global banks
8 of the leading 10
private equity firms
90%+ client subscription renewal rate

Analytics